Patents Issued in April 25, 2024
  • Publication number: 20240131061
    Abstract: The present disclosure relates to the preparation of citrullinated vimentin antigen-specific immune tolerogenic dendritic cells and a composition for preventing or treating heart failure after myocardial infarction comprising the same. According to the present disclosure, it is confirmed that immune tolerogenic dendritic cells differentiated by treating immature dendritic cells with citrullinated vimentin regulate the expression of immune-related factors and have an excellent therapeutic effect on heart failure caused by myocardial infarction.
    Type: Application
    Filed: August 10, 2023
    Publication date: April 25, 2024
    Applicants: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION, SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, Daegu Gyeongbuk Institute of Science and Technology
    Inventors: Kiyuk CHANG, Daehee HWANG, Min-Sik KIM, Eunmin KIM, Eun Hye PARK, Chan Woo KIM
  • Publication number: 20240131062
    Abstract: The spray dried plasma by the nature of its characteristics and the process by which it is made allows for a dried plasma with reduced pathogens. It has at least three aspects of pathogen reduction that results in a plasma product with reduced or no pathogens. The first aspect relates to a spray drying disposable and machine that eliminates or minimizes the introduction of pathogens into the spray drying process and is referred to as the anti-contamination process. The second aspect of pathogen reduction relates to the spray drying process and parameters that reduces pathogens that may be present in the donor plasma, and/or inhibit pathogen growth and/or pathogen proliferation introduced by the donor plasma. The third aspect results in reduced pathogens occurring during storage of the dried plasma wherein the manufacturing and storage conditions are such that pathogens are reduced, and/or pathogen growth and/or pathogen proliferation are inhibited.
    Type: Application
    Filed: September 14, 2023
    Publication date: April 25, 2024
    Applicant: Velico Medical, Inc.
    Inventors: Mark A. Popovsky, Lisa A. Buckley, Jihae Sohn, Evan P. Ordway, Qiyong Peter Liu, Robert R. Andrews, Herman E. Snyder, William J. Merritt, Clair Strohl, Russell J Barron
  • Publication number: 20240131063
    Abstract: The present invention relates to a spray dried plasma composition having one or more of the following characteristics: when reconstituted, largely amorphous and has no cholesterol crystals; when reconstituted, the mean size of large particulates is reduced; has low residual moisture; reconstitutes rapidly in under four minutes; highly stable when stored under refrigeration, at room temperature or at elevated temperatures and allows for storage for longer periods of time; when reconstituted, exhibits recovery of the most fragile of proteins, including von Willebrand's factor; when reconstituted with Sterile Water for Injection (SWFI), reconstituted plasma is at a pH that is near normal plasma pH, and does so without treatment or storage in CO2 or other pH adjustment.
    Type: Application
    Filed: September 14, 2023
    Publication date: April 25, 2024
    Applicant: Velico Medical, Inc.
    Inventors: Jihae Sohn, Lisa A. Buckley, Mark A. Popovsky, Qiyong Peter Liu, Herman E. Snyder, Evan P. Ordway, William J. Merritt, Robert R. Andrews, Clair Strohl
  • Publication number: 20240131064
    Abstract: The present invention provides improved and/or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of cancer with a V600 mutation with TILs as described herein in combination with BRAF inhibitors and/or MEK inhibitors.
    Type: Application
    Filed: December 10, 2021
    Publication date: April 25, 2024
    Inventor: Maria FARDIS
  • Publication number: 20240131065
    Abstract: An engineered immune cell for immunotherapy, which has a relatively high persistence and/or survival rate of transplantation in a host organism, and a preparation method therefor.
    Type: Application
    Filed: February 25, 2022
    Publication date: April 25, 2024
    Applicant: CRAGE MEDICAL CO., LIMITED
    Inventors: Zonghai LI, Zhimin SHI
  • Publication number: 20240131066
    Abstract: Described herein are methods using CRISPR-Cas9 and DNA templates that can generate chimeric antigen receptors (CARs) on T cells to target the cell surface protein urokinase Plasminogen Activator Receptor (uPAR) on senescent cells. Also described are methods of preparing CAR T cells, their use to treat neurodegenerative disease, stroke, craniocerebral trauma and/or accident, or elderly individuals in need of treatment for aging.
    Type: Application
    Filed: April 2, 2023
    Publication date: April 25, 2024
    Inventors: Krishanu Saha, Lauren Sarko
  • Publication number: 20240131067
    Abstract: Disclosed are methods of eliminating at least one target cell in a subject, comprising administering to the subject an effective amount of a composition comprising a plurality of immune cells, wherein each immune cell of the plurality expresses one or more chimeric ligand receptor(s) (CLR(s)) that each specifically bind to a target ligand on the at least one target cell, wherein specifically binding of the one or more CLR(s) to the target activates the immune cell, and wherein the activated immune cell induces death of the target cell. Exemplary target cells include, but are not limited to, hematopoietic stem cells (HSCs).
    Type: Application
    Filed: July 11, 2023
    Publication date: April 25, 2024
    Inventors: Eric M. OSTERTAG, Devon SHEDLOCK, Julian David DOWN
  • Publication number: 20240131068
    Abstract: The disclosure relates to immune cells comprising one or more vectors comprising a nucleic acid sequence encoding a chimeric antigen receptor specific for CD19 and a nucleic acid sequence encoding an enhancer of T cell priming (e.g., IL-18), compositions comprising the T cells, and methods of generating and/or using the T cells to treat diseases associated with the expression of CD19.
    Type: Application
    Filed: October 17, 2023
    Publication date: April 25, 2024
    Applicants: Kite Pharma, Inc., The Trustees of the University of Pennsylvania
    Inventors: Neil C. Sheppard, Yanping Luo, David Barrett, Regina Young
  • Publication number: 20240131069
    Abstract: Provided herein are tumor-infiltrating lymphocytes (TILs) engineered to express a membrane-bound interleukin 15 (mbIL15). The mbIL15 TILs can be expanded in vitro using a rapid expansion protocol without the use of exogenous interleukin 2 (IL2) and can be used in adoptive cell therapy without concomitant use of an exogenous cytokine such as IL2. The TIL can be further engineered such that the mbIL15 is operably linked to one or more drug responsive domains (DRDs), polypeptides that can regulate the abundance and/or activity of the IL15 upon binding of the DRD with a ligand. Also provided herein are components for making the modified TILs and methods for making and using the modified TILs.
    Type: Application
    Filed: November 2, 2023
    Publication date: April 25, 2024
    Applicant: OBSIDIAN THERAPEUTICS, INC.
    Inventors: Mithun Khattar, Shyamsundar Subramanian, Rachel Burga, Michelle Lynn Ols, Jan ter Meulen, Kyle Pedro, Jeremy Hatem Tchaicha
  • Publication number: 20240131070
    Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target uPAR and cells comprising such uPAR-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the uPAR-targeted antigen-recognizing receptors for treatment.
    Type: Application
    Filed: December 11, 2023
    Publication date: April 25, 2024
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.
    Inventors: Scott W. Lowe, Michel Sadelain, Corina Amor Vegas, Paul Balderes, Ivo C. Lorenz, Zeda Zhang
  • Publication number: 20240131071
    Abstract: Provided herein are compositions, such as, for example, CXCL 10-secreting antigen presenting cells, and methods for ultrasound-induced blood-brain bander disruption (e.g., low-intensity pulsed ultrasound (LIPU)) to treat a brain cancer in a mammalian subject.
    Type: Application
    Filed: March 9, 2022
    Publication date: April 25, 2024
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Amy B. HEIMBERGER
  • Publication number: 20240131072
    Abstract: Activity-inducible fusion proteins whose activity is post-translationally regulated utilizing a hsp90 binding domain and a drug molecule are described. In the absence of the drug molecule, the activity-inducible fusion proteins are inactivated but can be activated by a relevant physiological parameter in the presence of the drug molecule. Examples of the activity-inducible fusion proteins include chimeric antigen receptors (CAR) wherein the relevant physiological parameter is antigen binding.
    Type: Application
    Filed: February 11, 2022
    Publication date: April 25, 2024
    Applicant: Seattle Children's Hospital d/b/a Seattle Children's Research Institute
    Inventors: Ryan Koning, Adam Johnson, Chris Saxby, Michael C. Jensen, Ian Blumenthal, Aquene Reid
  • Publication number: 20240131073
    Abstract: Provided herein are compositions, kits, and methods for manufacturing cells for adoptive cell therapy comprising engineered immune cells that overexpress miR200c and/or EpCAM.
    Type: Application
    Filed: February 18, 2022
    Publication date: April 25, 2024
    Inventors: Morgan HUSE, Minggang ZHANG
  • Publication number: 20240131074
    Abstract: Anti-PSMA antibodies (e.g., UniAbs™) and CAR-T structures are disclosed, along with methods of making such antibodies and CAR-T structures, compositions, including pharmaceutical compositions, comprising such antibodies and CAR-T structures, and their use to treat disorders that are characterized by the expression of PSMA.
    Type: Application
    Filed: February 25, 2022
    Publication date: April 25, 2024
    Inventors: Starlynn Clarke, Brian Avanzino, Kevin Dang, Nathan Trinklein, Katherine Harris
  • Publication number: 20240131075
    Abstract: Methods are disclosed for treating an autoimmune disorder in a subject in need thereof. These methods include administering to the subject a pharmaceutical preparation comprising isolated matrix bound vesicles (MBV) derived from extracellular matrix. The administration can be systemic. In some embodiments, the subject has rheumatoid arthritis or psoriasis.
    Type: Application
    Filed: October 22, 2020
    Publication date: April 25, 2024
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Stephen Badylak, George S. Hussey, Raphael Crum
  • Publication number: 20240131076
    Abstract: Disclosed are novel compositions of matter and treatment methods for reducing and/or reversing epilepsy through administration of mesenchymal stem cells in order to induce immune modulation and/or regenerative processes.
    Type: Application
    Filed: October 23, 2023
    Publication date: April 25, 2024
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Thomas E. ICHIM, Timothy G. DIXON, James VELTMEYER
  • Publication number: 20240131077
    Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
    Type: Application
    Filed: September 20, 2023
    Publication date: April 25, 2024
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Irina Klimanskaya, Robert P. Lanza
  • Publication number: 20240131078
    Abstract: The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.
    Type: Application
    Filed: December 11, 2023
    Publication date: April 25, 2024
    Applicant: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • Publication number: 20240131079
    Abstract: The present disclosure provides a composition comprising extracellular vesicles (EVs) derived from induced pluripotent stem cells (iPSCs) or embryonic stem cells (ESCs). The present EVs possess immunoregulatory functions that are distinct from those of EVs derived from mesenchymal stem cells. The present EVs can be used to treat or modulate immune responses in diseases such as cancer or autoimmune diseases.
    Type: Application
    Filed: March 4, 2022
    Publication date: April 25, 2024
    Applicant: The Regents of the University of California
    Inventors: Jana ZARUBOVA, Mohammad Mahdi HASANI-SADRABADI, Song Li
  • Publication number: 20240131080
    Abstract: A method of generating an induced trophoblast stem cell (iTSC) from a human cell is provided. Accordingly there is provided a method comprising expressing within a human cell GATA3 and OCT4 transcription factors, under conditions which allow generation of an iTSC from the cell. Also provided is a method of rejuvenating and/or de-differentiating a human cell. Also provided are nucleic acid constructs, protein preparation, isolated human cells, human iTSCs, rejuvenated cells and de-differentiated cells.
    Type: Application
    Filed: December 13, 2023
    Publication date: April 25, 2024
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Yossi BUGANIM, Moriyah Naama SHACHAM
  • Publication number: 20240131081
    Abstract: The present disclosure relates to a novel Akkermansia strain and a use thereof. The novel Akkermansia HB03 strain (Akkermansia sp. HB03) provided in the present disclosure lacks toxic genes and thus does not cause side effects in vivo, and also exhibits excellent anti-cancer activity. Therefore, it can be widely used in the development of agents for preventing or treating cancer.
    Type: Application
    Filed: September 24, 2020
    Publication date: April 25, 2024
    Applicant: HEALTHBIOME
    Inventors: Jinhoi SONG, Jun Beom YOON, Mi Jin SON, Da Young SONG
  • Publication number: 20240131082
    Abstract: The present disclosure relates to compositions comprising preparations of uncultured fecal bacteria, methods of manufacturing the compositions, and methods of using the compositions to treat a disorder related to a gut dysbiosis.
    Type: Application
    Filed: October 18, 2020
    Publication date: April 25, 2024
    Applicant: Finch Therapeutics Holdings LLC
    Inventors: Mark SMITH, Sonia TIMBERLAKE, Zain KASSAM, Anh-Thu Elaine VO, John HENSKE, Ylaine GERARDIN, Rotem Gura SADOVSKY
  • Publication number: 20240131083
    Abstract: Methods and compositions related to pharmaceutical agents, pharmaceutical compositions, and solid dosage forms comprising animal hemoglobin and bacteria or agents of bacterial origin are provided herein.
    Type: Application
    Filed: December 21, 2021
    Publication date: April 25, 2024
    Inventor: Alexander Bank
  • Publication number: 20240131084
    Abstract: This application provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments, and methods for making, storing and using them, including formulations that effectively preserve microbial cell viability during freeze-thaw or freeze-drying. Compositions provided herein are useful for treating various diseases or conditions such as autism spectrum disordor, Crohn's Disease, ulcerative colitis, irritable bowel syndrome, and recurrent or primary C. difficile infection.
    Type: Application
    Filed: December 21, 2023
    Publication date: April 25, 2024
    Applicant: Finch Therapeutics Holdings LLC
    Inventor: Bharat DIXIT
  • Publication number: 20240131085
    Abstract: The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of living microorganisms and one or more pharmaceutically acceptable water absorbing excipient(s), wherein the composition has a water content, determined according to European Pharmacopoeia 9.4, section 2.5.12., from 0.5 to 30% with respect the total weight of the composition. The invention also provides processes for its preparation as well as it use in therapy. The live-cell based composition of the invention is stable at mild conditions.
    Type: Application
    Filed: December 15, 2023
    Publication date: April 25, 2024
    Applicants: INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER (IDIBAPS), FUNDACIÓ CLÍNIC PER A LA RECERCA BIOMÈDICA, HOSPITAL CLÍNIC DE BARCELONA, UNIVERSITAT DE BARCELONA
    Inventors: Josep M. SUÑÉ NEGRE, Alex SORIANO VILADOMIU, Andrea AIRA GOMEZ, Csaba FEHER
  • Publication number: 20240131086
    Abstract: The present disclosure provides use of Clostridium ghonii combined with a tumor angiogenesis inhibitor in preparing a pharmaceutical product for treating a tumor. The present disclosure further provides a drug for treating a tumor, where the drug includes active ingredients of Clostridium ghonii and a tumor angiogenesis inhibitor.
    Type: Application
    Filed: October 9, 2022
    Publication date: April 25, 2024
    Inventors: Yong Wang, Yuanyuan Liu, Wenhua Zhang, Yanqiu Xing, Shaopeng Wang, Dan Wang, Hong Zhu, Xinglu Xu, Shengbiao Jiang, Xiaonan Li, Jiahui Zheng, Rong Zhang, Dongxia Yang, Yuxia Gao, Shili Shao, Ting Han
  • Publication number: 20240131087
    Abstract: Disclosed herein are compositions and methods for treating periodontal disease.
    Type: Application
    Filed: September 24, 2023
    Publication date: April 25, 2024
    Inventors: Linden Hu, Louis Cornacchione
  • Publication number: 20240131088
    Abstract: The present invention falls within the technical field of aquaculture, and specifically, the invention relates to a specific solution for preventing and treating bacterial diseases using a Lactococcus lactic lactic acid bacterium transformed to produce an interferon type II (IFN II) immunostimulating cytokine, particularly interferon gamma (IFNg or IFNy). Said transformed bacterium has been deposited in the Chilean Microbial Genetic Resources Collection at INIA with accession number RGM 2416 dated 22 Oct. 2017.
    Type: Application
    Filed: September 14, 2023
    Publication date: April 25, 2024
    Inventors: Mario Cesar Gerardo TELLO REYES, Alvaro Eugenio SANTIBAÑEZ VARGA, Mick Philippe PARRA MARDONEZ, Diego Enrique PAINE CABRERA, Claudia Andrea ZAPATA ROJAS, Andrea Del Pilar GARCES FERNANDEZ
  • Publication number: 20240131089
    Abstract: The present invention relates to a composition for use in the treatment and/or prevention of a dry and/or sensitive skin condition in a subject. The composition comprises at least two bacterial species which decrease the levels of interleukin-17 and/or interleukin-23 in the subject, and/or increase the levels of interleukin-10 in the subject and/or improve gut barrier function in the subject. The at least two bacterial species may comprise Bifidobacterium animalis, Lactobacillus brevis, Lactobacillus reuteri and/or Lactococcus lactis.
    Type: Application
    Filed: February 17, 2022
    Publication date: April 25, 2024
    Inventor: Catherine O'Neill
  • Publication number: 20240131090
    Abstract: In particular, this invention refers to a composition comprising a probiotic combination comprising: a) at least one strain of the genus Lactobacillus selected from the species Lactobacillus plantarum; and c) at least one strain belonging to the genus Bifidobacterium selected from the species Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium infantis; wherein said composition is for use in a method for the prevention and/or treatment of chronic inflammatory bowel disease (Inflammatory Bowel Disease IBD).
    Type: Application
    Filed: March 28, 2022
    Publication date: April 25, 2024
    Inventors: Rosella MALANCHIN, Cristiana PIANGIOLINO, Silvia CASTEGNARO, Federica CARLOMAGNO, Chiara PESCIAROLI
  • Publication number: 20240131091
    Abstract: This disclosure provides for compositions (e.g., pharmaceutical compositions, dietary supplements, medical foods and food stuff), comprising combinations of live microbe populations for the treatment and/or prevention of immune system disorders and conditions related to inflammation, including both pathogen assisted conditions and conditions that are independent of pathogens. Included with the present disclosure are methods for use of the compositions, and methods for selecting microbial entities to formulate the compositions of the disclosure.
    Type: Application
    Filed: September 27, 2023
    Publication date: April 25, 2024
    Inventors: Eric Michael Schott, Gerardo V. Toledo, Maria Juliana Soto-Giron, Alicia Eve Ballok, Ryan Green, Mark Charbonneau
  • Publication number: 20240131092
    Abstract: The present application relates to a novel bacteriophage having Clostridium perfringens-specific bactericidal effect and an antibacterial composition comprising same, the novel bacteriophage CJ_CP_20-11-1 having Clostridium perfringens-specific bactericidal effect, and being superbly acid and heat resistant to allow wide use in antibiotics, feed and additives therefor, beverages and additives therefor, disinfectants, detergents, and the like to prevent or treat infectious diseases caused by Clostridium perfringens.
    Type: Application
    Filed: June 14, 2021
    Publication date: April 25, 2024
    Applicant: CJ CheilJedang Corporation
    Inventors: Jong Soo JEON, Ji Eun KIM, Jun Ok MOON, Jong Pyo CHAE, Yu Jin KIM, Seung Eun LEE
  • Publication number: 20240131093
    Abstract: The present invention relates to adeno-associated viral (AAV) particles encoding siRNA molecules and methods for treating Huntington's Disease (HD).
    Type: Application
    Filed: July 12, 2023
    Publication date: April 25, 2024
    Inventors: Dinah Wen-Yee Sah, Fen Chen, Pengcheng Zhou, Xin Wang, Yanqun Shu, Jinzhao Hou, Jochen Deckert, Markus Hossbach
  • Publication number: 20240131094
    Abstract: In The present invention relates in a first aspect to the use of influenza virus defective interfering particles in the prophylactic or therapeutic treatment of coronaviridae infection. In particular, it has been recognized that defective interfering particles of influenza A have beneficial effects in the treatment of SARS coronavirus infection, in particular, SARS-CoV-2 infection. Further, the present invention relates to a pharmaceutical composition for use in treating coronaviridae infection, in particular SARS-CoV-2. In a further aspect, methods for the prophylactic or therapeutic treatments of coronaviridae based on the administration of DIFs are disclosed.
    Type: Application
    Filed: February 18, 2022
    Publication date: April 25, 2024
    Inventors: Sascha KUPKE, Udo REICHL, Marc Dominique HEIN, Dunja BRUDER, ulfert RAND
  • Publication number: 20240131095
    Abstract: The disclosure provides artificial viral compositions for use in treating cancer or a hyperproliferative disorder in a subject to whom the compositions are administered, as well as to methods of making and using the compositions.
    Type: Application
    Filed: April 14, 2021
    Publication date: April 25, 2024
    Inventors: Chad M. Moles, Peter E. Weijmarshausen
  • Publication number: 20240131096
    Abstract: The present disclosure provides methods of treating cancer using complementary transgenic oncolytic viruses and genetically engineered CAR T cells. In one embodiment, the oncolytic virus comprises nucleotide sequences encoding CD19, or CD19 and IL-12, and the genetically engineered T cells express a chimeric antigen receptor that recognizes CD19.
    Type: Application
    Filed: October 23, 2023
    Publication date: April 25, 2024
    Applicants: Broaden Bioscience and Technology Corp, Orgenesis, Inc, Joint BioSciences Ltd
    Inventors: BUO CHEN, GUOQING ZHOU, XIANGGUM LI
  • Publication number: 20240131097
    Abstract: The instant invention relates to seaweed extract compositions, processes for isolation, isolated active agents, and methods of treating disease, disorders and conditions in a subject, including, reactive oxygen species (ROS)-mediated diseases and diseases mediated through the activation of the Nrf2-ARE (antioxidant response element) pathway, including proliferative diseases and disorders, Alzheimer's disease, stroke, and certain diseases and disorders of aging and associated with aging and exposure, by use of the extracts, compounds, and compositions thereof.
    Type: Application
    Filed: October 24, 2023
    Publication date: April 25, 2024
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Hendrik Luesch, Michelle S. Bousquet
  • Publication number: 20240131098
    Abstract: Proposed are pharmaceutical compositions and health functional foods containing a Ganoderma lucidum fruiting body extract as an active ingredient for preventing, treating, or ameliorating thrombosis. The extract exhibits strong antithrombotic activity by inhibiting thrombosis-related enzymes and blood coagulation factors, has excellent thermal stability, and exhibits no loss of blood coagulation factor inhibitory effect and thrombogenic enzyme inhibitory effect even in acidic conditions of pH 2 and in plasma. Therefore, the Ganoderma lucidum fruiting body extract is expected to be used for the prevention and treatment of thrombosis, which causes ischemic stroke and hemorrhagic stroke, by improving blood circulation. The Ganoderma lucidum fruiting body extract is very useful in the pharmaceutical and food industries.
    Type: Application
    Filed: February 23, 2023
    Publication date: April 25, 2024
    Applicant: Andong National University Industry-Academic Cooperation Foundation
    Inventor: Ho Yong SOHN
  • Publication number: 20240131099
    Abstract: Described herein are novel compositions comprising a Cannabis component selected from the group consisting of: a cannabinoid, a flavonoid and a terpenoid; and a protein, selected from the group consisting of whey and a plant protein. According to an embodiment, the Cannabis component is non-covalently bound to the whey or to the plant protein. The plant protein may be selected from the group consisting of: soy protein, pea protein, rice protein, hemp protein, and hops protein or other plant derived protein.
    Type: Application
    Filed: December 31, 2023
    Publication date: April 25, 2024
    Applicant: DAY THREE LABS MANUFACTURING INC.
    Inventors: Shimon LECHT, Olga GABAY, Adi LAHIANI HAFZADI, William Z. LEVINE
  • Publication number: 20240131100
    Abstract: An oral product comprising nano-sized, heat tolerable, shelf stable peptides and enzymes. Once the peptides and enzymes are inside the body of a user, they dimerize the nucleic acids of viruses, bacteria and fungi. Thus, the peptides and enzymes are capable of inactivating the genome of pathogens, including without limitation, SARS-CoV-2 and Influenza A/CA/04/2009 (H1N1) virus.
    Type: Application
    Filed: October 24, 2022
    Publication date: April 25, 2024
    Inventor: Mitchell Lynn Tate
  • Publication number: 20240131101
    Abstract: The present disclosure provides a method for extracting and purifying total flavonoids from Carthamus tinctorius L. leaf, and use thereof, and belongs to the technical field of extraction and use of active ingredients of traditional Chinese medicine. The method includes: heating and refluxing Carthamus tinctorius L. leaf with ethanol to obtain a mixture, where the ethanol and Carthamus tinctorius L. leaf are at a volume ratio of (20-30):1; concentrating the mixture to form a concentrated filtrate, and adsorbing the concentrated filtrate with a macroporous resin; eluting a resulting adsorbed macroporous resin with ethanol, and collecting an obtained eluate; and concentrating the eluate until there is no residual ethanol, and drying in sequence to obtain a TFFCL powder. In the present disclosure, Carthamus tinctorius L. leaf is analyzed, the TFFCL is extracted, and applications of extracted total flavonoids (TFs) are studied, thereby better utilizing the resources of Carthamus tinctorius L.
    Type: Application
    Filed: October 16, 2023
    Publication date: April 25, 2024
    Applicant: Shaanxi University of Chinese Medicine
    Inventors: Zhishu TANG, Lin CHEN, Zhongxing SONG
  • Publication number: 20240131102
    Abstract: The invention is directed to an aqueous extract of Eruca sativa (arugula) leaves that has antimicrobial activity on Gram-positive bacteria and mycoplasmas. The extract may be purified away from solid or insoluble components, standardized based on the weight of its non-aqueous or solid content, assayed for antimicrobial activity, and provided in an aseptic or sterile form for pharmaceutical use. It may be used to kill or inhibit the growth of microorganisms such as Gram positive bacteria, promote wound healing, or as prophylaxis against host colonization or infection by a microorganism.
    Type: Application
    Filed: December 29, 2023
    Publication date: April 25, 2024
    Applicant: Imam Abdulrahman Bin Faisal University
    Inventors: Ines Mohsen HAMMAMI, Azzah Ibrahim ALGHAMDI
  • Publication number: 20240131103
    Abstract: The present invention relates to the novel topical composition of arthritis emulgel. The present invention specifically relates to novel topical composition of arthritis emulgel comprising combination of active ingredients and pharmaceutically acceptable excipients. The present invention more specifically relates to novel composition of arthritis emulgel comprising combination of Curcumin (using Force C3™ augmented absorption technology), Boswellia serrata extract, Methyl salicylate, Menthol as active ingredients and pharmaceutically acceptable excipients. The present invention more specifically relates to novel composition, wherein composition optionally contains one or more of Ginger extract, Glucosamine sulphate and Chondroitin sulphate. The present invention also relates to process for the preparation of novel topical composition of arthritis emulgel comprising the steps of dissolving, mixing, adding, sonicating, adjusting the pH and stirring.
    Type: Application
    Filed: February 17, 2022
    Publication date: April 25, 2024
    Inventors: Chandanmal Pukhraj Bothra, Hemanth Kumar Bothra, Elayaraja Natarajan, Jyolsna Agnes Jose, Shailendra Thakur
  • Publication number: 20240131104
    Abstract: This invention is directed to oral botanical compositions comprising plant extracts, methods of preparing the same, and methods of using the same for treating an infection.
    Type: Application
    Filed: February 11, 2022
    Publication date: April 25, 2024
    Inventors: Jeffrey Olaf Langland, Bertram Jacobs
  • Publication number: 20240131105
    Abstract: A method of treating a condition comprising: administering a composition, wherein the composition comprises a Chelidonium majus extract and a tariquidar component, and wherein the condition is a cancer related to a gene selected from the group of genes including one or more of: STAG1A, STAG1B, FAM72C, ATF7-NPFF, SLX1B, MTRNR2L10, TMSB15A, Tb15, TbNB, TMSL8, TMSNB, TMSB15, TMSB15B, GP2, CSAG3, DNAJC25-GNG10, PIF1, BIVM, ERCC5, CSNK2A3, CT47A10, DRD2, BRINP2, PNPLA3, KLK13, and/or SERPINA6.
    Type: Application
    Filed: October 23, 2023
    Publication date: April 25, 2024
    Inventors: Igor O. Nasonkin, Charles Irving
  • Publication number: 20240131106
    Abstract: Provided is a traditional Chinese herbal composition for treating pulmonary nodules, a preparation method thereof, and a honeyed pill. The composition comprises: 30 parts by weight of Ziziphi Spinosae Semen, 20-30 parts by weight of Rehmaniae Radix, 30 parts by weight of Trichosanthis Radix, 40-50 parts by weight of Paeoniae Radix Alba, 30 parts by weight of Coicis Semen Preparata, 20 parts by weight of Ginseng Radix et Rhizoma, 10 parts by weight of Olibanum, 10 parts by weight of Myrrha, 20-30 parts by weight of Testudinis Carapax et Plastrum Preparata Cum Aceto, 20-30 parts by weight of Trionycis Carapax Preparata Cum Aceto, 30 parts by weight ofAgrimoniae Herba, 10-20 parts by weight ofAlpiniae Oxyphyllae Fructus, 5 parts by weight of Toosendan Fructus, 20 parts by weight of Poria, 10 parts by weight of Platycodonis Radix, and 10 parts by weight of Polygalae Radix.
    Type: Application
    Filed: October 18, 2022
    Publication date: April 25, 2024
    Applicant: Changchun University of Traditional Chinese Medicine
    Inventors: Tan Wang, Shaodan Hu, Mengzhu Chen, Yujiao Liu, Yannan Xu, Wenlong Qi, Keju Wang, Ziyuan Wang
  • Publication number: 20240131107
    Abstract: A botanical antiviral nutritional supplement includes ground Achillea Millefolium, ground Bryophyllum Pinnatum, ground Sambucus Nigra, ground Neurolaena Lobata, ground Verbascum Thapsus, ground Morinda Citrifolia, ground Prunella Vulgaris, and ground Salvia Officinalis. A method of producing the antiviral nutritional supplement includes drying the botanical ingredients; grinding the dried ingredients; and blending the ground, dried ingredients. The supplement is believed to improve the health of a person infected with a virus and to relieve brain fog.
    Type: Application
    Filed: January 4, 2024
    Publication date: April 25, 2024
    Inventor: Michael Wayne Dockery
  • Publication number: 20240131108
    Abstract: The present invention discloses biodegradable glass based on an amino acid, a peptide and a derivative, as well as the preparation method and use thereof. The main raw material of the glass is one or more of an amino acid, a peptide, a derivative or salt thereof. Compared with traditional glass, the glass of the present invention has significant advantages such as high biocompatibility, biodegradability, being 3D printable, and being compostable, etc., and its preparation process is simple and green, which can effectively avoid the influence of the traditional glass on the ecological environment. The glass of the present invention has a wide range of applications in the fields such as medicine, building material, chemical industry, food, electronics, national defense, etc., including but not limited to tissue engineering, tooth/bone repair, drug sustained-release, cell/protein sequestration, optical fiber communication, coatings, precision instruments, etc.
    Type: Application
    Filed: September 29, 2021
    Publication date: April 25, 2024
    Inventors: Xuehai YAN, Ruirui XING, Chengqian YUAN
  • Publication number: 20240131109
    Abstract: The application is directed a composition comprising organic acid (e.g., ascorbic acid), glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically-acceptable salt thereof, or any combination thereof, and methods of using the same. In certain aspects the application is directed to glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically-acceptable salt thereof; and an organic acid; wherein the molar ratio is about 0.5-1:1. The composition can further comprises a bicarbonate salt, wherein the molar ratio is about 0.1-0.5:0.5-1:1.
    Type: Application
    Filed: December 21, 2023
    Publication date: April 25, 2024
    Inventors: Dan COPELAND, Carolyn DURHAM
  • Publication number: 20240131110
    Abstract: The present invention concerns methods of reducing bone loss and/or stimulating bone production comprising administering an effective amount of a peptide comprising the amino acid sequence SVTEQGAELSNEER (SEQ ID NO:1), or variants thereof, to a patient and/or bone cells. The present invention also concerns methods of treatment and/or prophylaxis of musculoskeletal loss and/or damage in a patient, comprising administering an effective amount of the peptide.
    Type: Application
    Filed: October 16, 2023
    Publication date: April 25, 2024
    Inventors: George Edward Rainger, Helen McGettrick, Myriam Chimen